AME
62
3
MOS
29
6
STX
46
-2
MAC
65
3
GILD
26
2
NFLX
59
-3
GPS
78
17
KEY
37
6
MSI
50
3
DLTR
48
4
VIX
36
-21
AON
36
4
PFE
35
3
XOM
50
6
CMS
71
4
ADM
37
7
ED
37
6
EW
44
-2
PNW
52
4
PGR
70
5
AME
62
3
MOS
29
6
STX
46
-2
MAC
65
3
GILD
26
2
NFLX
59
-3
GPS
78
17
KEY
37
6
MSI
50
3
DLTR
48
4
VIX
36
-21
AON
36
4
PFE
35
3
XOM
50
6
CMS
71
4
ADM
37
7
ED
37
6
EW
44
-2
PNW
52
4
PGR
70
5
Financhill
Back

Fate Therapeutics 10K Form

Sell
50

FATE
Fate Therapeutics

Last Price:
3.70
Seasonality Move:
-0.85%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q FATE/Fate Therapeutics Quarterly
2023-08-08 10Q FATE/Fate Therapeutics Quarterly
2023-05-03 10Q FATE/Fate Therapeutics Quarterly
2022-11-03 10Q FATE/Fate Therapeutics Quarterly
2022-08-03 10Q FATE/Fate Therapeutics Quarterly
2022-05-04 10Q FATE/Fate Therapeutics Quarterly

Receive FATE News And Ratings

See the #1 stock for the next 7 days that we like better than FATE

FATE Financial Statistics

Sales & Book Value

Annual Sales: $63.53M
Cash Flow: $-33.44M
Price / Cash Flow: 0
Annual Sales: $3.74
Price / Book: 0.98

Profitability

EPS (TTM): -1.92000
Net Income (TTM): $-190.05M
Gross Margin: $0
Return on Equity: -44.98%
Return on Assets: -33.52%

Fate Therapeutics Earnings Forecast

Key Fate Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 4 years for FATE is 0.00%.
  • The Selling, General & Administrative Expenses for FATE have been equal to 128.20% of Gross Profit Margin.
  • The Research & Development expenses have been 271.66% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of FATE is -253.30% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

Fate Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FATE
CUSIP: 31189P
Website: fatetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.69
Quick Ratio: 8.47

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FATE Technical Analysis vs Fundamental Analysis

Sell
50
Fate Therapeutics (FATE) is a Sell

Is Fate Therapeutics a Buy or a Sell?

  • Fate Therapeutics stock is rated a Sell
    The current Fate Therapeutics [FATE] share price is $3.68. The Score for FATE is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.